Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $24.38, for a total value of $121,900.00. Following the sale, the chief operating officer now owns 263,306 shares of the company's stock, valued at approximately $6,419,400.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Akero Therapeutics Stock Performance
Shares of AKRO opened at $23.18 on Thursday. The business's 50 day moving average is $24.42 and its two-hundred day moving average is $23.72. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $58.38. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -8.13 and a beta of -0.38. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.17). Analysts forecast that Akero Therapeutics, Inc. will post -4.06 EPS for the current fiscal year.
Institutional Investors Weigh In On Akero Therapeutics
He Is Giving Away Bitcoin
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
Institutional investors and hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC acquired a new stake in Akero Therapeutics in the fourth quarter worth $28,000. Point72 Hong Kong Ltd acquired a new stake in Akero Therapeutics in the first quarter worth $32,000. KBC Group NV acquired a new stake in Akero Therapeutics in the fourth quarter worth $36,000. Quarry LP grew its stake in shares of Akero Therapeutics by 40.0% in the fourth quarter. Quarry LP now owns 1,750 shares of the company's stock worth $41,000 after purchasing an additional 500 shares in the last quarter. Finally, Strs Ohio grew its stake in shares of Akero Therapeutics by 100.0% in the fourth quarter. Strs Ohio now owns 2,000 shares of the company's stock worth $46,000 after purchasing an additional 1,000 shares in the last quarter.
Wall Street Analyst Weigh In
AKRO has been the topic of a number of research analyst reports. UBS Group raised their price target on Akero Therapeutics from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, March 5th. HC Wainwright boosted their target price on Akero Therapeutics from $40.00 to $43.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $39.00.
Check Out Our Latest Stock Report on AKRO
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
